Theravance, Inc. engages in the discovery, development, and commercialization of small molecule medicines in the United States. It provides medicines for respiratory disease, bacterial infections, and gastrointestinal motility dysfunction therapeutic areas. Its development programs include Telavancin, a bactericidal injectable antibiotic in Phase III clinical studies to treat serious Gram-positive bacterial infections; and Heterodimer in preclinical development stage for bacterial infections. The company is developing long-acting beta2 agonist product candidates intended for the treatment of asthma and chronic obstructive pulmonary disease. Its development programs for Gastrointestinal...